Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Inhibitor”

769 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 769 results

Early research (Phase 1)WithdrawnNCT03605589
What this trial is testing

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Who this might be right for
Leukemia, B-cellLymphoma, B-Cell
Children's Hospital Medical Center, Cincinnati
Testing effectiveness (Phase 2)Looking for participantsNCT07495215
What this trial is testing

A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection

Who this might be right for
Hepatocellular Carcinoma (HCC)
Yinghua Xu 20
Not applicableLooking for participantsNCT07041320
What this trial is testing

Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)Elderly (People Aged 65 or More)
Anhui Chest Hospital 40
Testing effectiveness (Phase 2)UnknownNCT04189094
What this trial is testing

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Who this might be right for
Small Cell Lung Cancer Limited Stage
Zhejiang Cancer Hospital 140
Testing effectiveness (Phase 2)UnknownNCT04371796
What this trial is testing

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Who this might be right for
Lung DiseasesNeoplasmsRespiratory Tract Diseases+2 more
Sichuan Cancer Hospital and Research Institute 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Testing effectiveness (Phase 2)UnknownNCT05311566
What this trial is testing

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Who this might be right for
Cervical CarcinomaChemoradiotherapyAnti-programmed Cell Death Receptor 1+6 more
Lei Li 92
Not applicableNot Yet RecruitingNCT07340502
What this trial is testing

TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma

Who this might be right for
HCC
Tongji Hospital 364
Large-scale testing (Phase 3)Study completedNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 479
Testing effectiveness (Phase 2)Study completedNCT04796194
What this trial is testing

Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

Who this might be right for
Advanced Melanoma
Lytix Biopharma AS 23
Early research (Phase 1)Active Not RecruitingNCT05615142
What this trial is testing

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Who this might be right for
NSCLCLow Dose RadiotherapyStereotactic Body Radiotherapy+1 more
Sichuan University 9
Early research (Phase 1)Ended earlyNCT05904496
What this trial is testing

BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
BeiGene 44
Testing effectiveness (Phase 2)UnknownNCT05137886
What this trial is testing

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma, AdultRelapseRefractory Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 47
Testing effectiveness (Phase 2)Ended earlyNCT03637803
What this trial is testing

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Who this might be right for
OncologySolid TumorNon Small Cell Lung Cancer+3 more
4D pharma plc 63
Testing effectiveness (Phase 2)UnknownNCT06304987
What this trial is testing

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer
Beijing Friendship Hospital 50
Large-scale testing (Phase 3)Active Not RecruitingNCT05374512
What this trial is testing

Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Who this might be right for
Breast Cancer
AstraZeneca 644
Testing effectiveness (Phase 2)Study completedNCT03977467
What this trial is testing

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Who this might be right for
Non-Small Cell Lung CancerSolid Tumor
SCRI Development Innovations, LLC 46
Testing effectiveness (Phase 2)UnknownNCT05115500
What this trial is testing

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Who this might be right for
CarcinomaSolid Tumor
Second Affiliated Hospital of Soochow University 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT06933251
What this trial is testing

PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal Cancer (LARC)
Guangdong Provincial People's Hospital 30
Early research (Phase 1)Study completedNCT03910530
What this trial is testing

INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid Tumors
Incyte Biosciences Japan GK 18
Load More Results